http://www.globalwatchservice.com/pages/TwoColumns.aspx?PageID=439&ProfileID=1010&UseRef=False

Heres a recommendation from Hoods mind you since then ERX has had a bit of dilution, but i would not say no to 7.75p

hurry hurry hurry.. news could be out any day

You can get a job at the fair otherwise selling the rides!

ok last chance, really is!!! your iether in or your out

Sorry PH, ITS DRIVERS FAULT he told me how to do it !! cant stop now !! but good luck for next week : )

PH anything happening?

25th.. put it in ya diary

EiRx Therapeutics (EiRx)



Announces Triggering of First Success Milestone Payments with OSI
Pharmaceuticals for the License of EiRx's Apoptosis Drug Targets



EiRx Therapeutics plc ("EiRx"). (LSE:AIM: ERX), the healthcare company
specialising in the control of programmed life and death of cells (apoptosis) is
pleased to announce its first major milestone agreement since its flotation on
AIM earlier this year with a potential value of up to US $18.8 million.



Following a 12 month period of Evaluation and Option, OSI Pharmaceuticals
("OSIP"), has elected to licence and take forward four of EiRx's novel
apoptosis gene targets into drug discovery for oncology. OSI Pharmaceuticals
(headquartered in Melville, NY), is a leading biotechnology company focused on
the discovery, development, and commercialization of high-quality, next-
generation oncology products. A success fee for each target is payable by OSIP,
as part of a deal consisting of upfront access and consultancy fees, potential
success fees for each target elected by OSIP to license and potential milestone
payments based on successful commercialisation of a novel therapeutic with
respect to each such target.



Ian Hayes, Ph.D., Chief Executive Officer of EiRx Therapeutics plc., commented:
"We are delighted by this positive outcome, to the therapeutic evaluation of our
novel apoptosis gene targets, by OSIP. Apoptosis regulation is rapidly gaining
appreciation as a central factor for many diseases, not least cancer. In
additional to the further validation of EiRx's apoptosis gene target discovery
platform ALIBI(TM), our agreement provides the opportunity to rapidly develop some
of EiRx's proprietary targets for drug discovery, while working with - and
learning from - one of the global leaders in developing novel oncology products."



"Our initial collaboration with EiRx has been very productive and we are excited
to be moving to the next phase of this research in which we will evaluate the
potential of the targets for the discovery of small molecules capable of
inducing apoptosis," stated Neil Gibson, Ph.D., Vice President of Research at
OSI Pharmaceuticals, Inc.

potatohead who posted this news as i cannot find it ?

its an rns

OSI Pharmaceutical Starts New Tarceva Lung Cancer Trial
Thursday September 21st, 2006 / 13h48


DOW JONES NEWSWIRES
OSI Pharmaceuticals Inc. (OSIP) said it will start a Phase III study of its Tarceva drug as a targeted adjuvant treatment for certain non-small-cell lung-cancer patients who have undergone surgery.
The Melville, N.Y., drug developer said the once-daily medication is currently indicated for patients with non-small-cell lung cancer who did not respond to at least one round of chemotherapy and for some types of pancreatic cancer when used in combination with a specific type of chemotherapy.
OSI, which is developing the drug in concert with Genentech Inc. (DNA) and Roche Holding AG (RHHBY), said the study will enroll 945 patients in different locations around the world.
The study also will examine whether testing for a specific type of component in tumor tissue can help identify patients more receptive to treatment, OSI said.
-James DeWeese; 201-938-5400; AskNewswires@dowjones.com

It's not showing as an RNS in the UK?

oh yes it is

http://www.advfn.com/p.php?pid=nmona&cb=1161601588&article=7553880&symbol=LSE%3AERX

Found it at advfn on your link but not on any other site yet! Including London stock exchange

blimey... its from 2004.. I am merely pointing out we are now due 19mil from them

as well as the 19mil for the breast cancer deal

keep up!!!

PH not funny it's dated from your input so people will read it as such!
ADVFN for me cuts out after a few seconds so I didn't read the dates.
We know good news is coming just think before you put up a link without dating it!

PH can you put it bullet notes all the things expected and rough time scales?

Press Release News | Home

Researchers Advancing Blood Cancer Therapies Receive $42.75 Million in Grants From The Leukemia & Lymphoma Society
Posted on : Mon, 23 Oct 2006 11:04:00 GMT | Author : The Leukemia & Lymphoma Society
News Category : PressRelease


WHITE PLAINS, N.Y., Oct. 23 /PRNewswire/ -- The Leukemia & Lymphoma Society today announced it has awarded four new Specialized Center of Research (SCOR) grants, the Society's most ambitious and synergistic research initiative, bringing the program's total funding to $159 million since its inception in 2000.

Three of this year's SCOR recipients will receive $1.25 million per year for five years, for a total of $6.25 million, and one will receive $1.05 million per year for five years, for a total of $5.25 million. In addition, the Society is renewing three existing SCORs for five more years.


The innovative SCOR program brings together teams of researchers representing different disciplines in a collaborative effort to discover new approaches to treat patients with leukemia, lymphoma or myeloma. Awards go to those groups that best demonstrate outstanding scientific promise and the synergy that will occur from their combined efforts.

"The four SCOR recipients selected this year have assembled teams that are pursuing new targets for drug therapy," said Marshall Lichtman, M.D., the Society's executive vice president, Research & Medical Programs. "In addition to lymphoma, acute myelogenous and lymphocytic leukemia, two understudied problems, infant leukemia and the myeloproliferative diseases are being investigated. The latter diseases are essentially three different forms of chronic myelogenous leukemia. A recently described mutation common to the myeloproliferative diseases provides an opportunity to develop the first specific treatment of these disorders. These SCOR grants represent an impressive addition of outstanding scientists and scientific goals to the Society's Specialized Centers program."

The recipients for 2006 are:

Frederick W. Alt, PhD., Howard Hughes Medical Investigator at Children's Hospital Boston; Janeway Professor of Pediatrics and Professor of Genetics at Harvard Medical School; Scientific Director of the CBR Institute for Biomedical Research. Dr. Alt received the Society's de Villiers International Achievement Award last year for his seminal work in immune cell function, genetic instability in cancer, and the DNA repair process that can prevent cancer-causing mutations. His SCOR will focus on the causes of B cell lymphomas and the development of new therapies for these tumors. To develop more effective treatments, Dr. Alt's team will focus on two fundamental properties of malignant B cells: B cell receptor (BCR) signaling and DNA repair-associated genetic abnormalities. They will identify pre-disposing genetic factors that are likely to serve as molecular targets for new therapies. The SCOR team also includes researchers from Dana-Farber Cancer Institute.

Carolyn A. Felix, MD, Children's Hospital of Philadelphia; Professor of Pediatrics at the University of Pennsylvania School of Medicine. Dr. Felix's research concentrates on improving the dismal outcome for infants with leukemia -- these blood cancers are characterized by chromosomal abnormalities called translocations which involve the breakage and abnormal recombination of a gene called MLL (Mixed Lineage Leukemia) with one of many partner genes. Dr. Felix's SCOR team will characterize the MLL leukemia stem cell from which all other leukemia cells derive, identify and develop agents that specifically target cells with MLL translocations, and learn in which infants these new drugs are most likely to be effective. Her team comprises researchers from the University of New Mexico Health Sciences Center, the Sidney Kimmel Comprehensive Center at Johns Hopkins University, Stanford University and Tulane University. The multi-faceted, multi-institutional team will collaborate with and access critical resources of the Children's Oncology Group in order to streamline advancement of new agents from the laboratory to affected infants.

Anthony Green, MD, PhD, FRCPath, University of Cambridge, Cambridge Institute for Medical Research Haematology. Prof. Green studies normal hematopoietic stem cells and the way they can give rise to haematological malignancies including the myeloproliferative disorders (MPDs). Research has shown that defects in one gene, JAK2, are present in most but not all patients with an MPD. This and other molecular discoveries will help develop new approaches to the diagnosis and treatment of these disorders. Prof. Green's SCOR, based in the United Kingdom, will bring together and provide infrastructural support for researchers from the Cambridge Institute of Medical Research, the MRC Laboratory of Molecular Biology, the Sanger Institute and Addenbrooke's Hospital. The SCOR will also benefit from Prof. Green's role as coordinator of the largest randomized MPD clinical trial and from collaboration with the UK MPD Study Group, a national network of MPD physicians.

Michael Thirman, MD, Associate Professor of Medicine and Director of Leukemia Biology, University of Chicago. Dr. Thirman's work is focused on critical genetic changes in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). His SCOR will develop and test novel agents that can target and disrupt the molecular pathways that result in the transformation of blood cells into cancer cells. The researchers will study the role of several genes that are critical to the development of leukemia and lymphoma. They will focus on the development of peptides and small molecules that can penetrate cancer cells and target pathways that are essential to survival. His SCOR is a collaboration with researchers from the University of Chicago, Albert Einstein College of Medicine in New York, and University of California San Diego.

In addition to the four new centers, the Society has renewed three SCORs led by Carl June, MD, University of Pennsylvania, whose SCOR is working on developing new immunotherapies for adults and children with blood cancers; Stephen Nimer, MD, Memorial Sloan-Kettering Cancer Center, whose team is working toward understanding how fusion proteins cause leukemias and might serve as new therapy targets; and Jerry Adams, PhD, Walter & Eliza Hall Institute of Medical Research, whose SCOR is trying to understand how the cell death process called apoptosis is blocked in blood cancer cells so that new, targeted drugs can be developed to effectively kill cancer cells.

SCOR is one of three integrated research programs established by the Society. The Career Development Program provides stipends to investigators of exceptional promise in the early stages of their careers, and the Translational Research Program encourages and supports outstanding investigative research that shows strong promise of translating biomedical knowledge into new treatments. The Society also bestows the Stohlman Scholar Award, given to scientists who hold faculty-level or equivalent positions at major research institutions and who are in the fifth year of their research.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society, headquartered in White Plains, NY, with 66 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The Society's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, the Society has invested more than $483 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the Society made 4.2 million contacts with patients, caregivers and healthcare professionals.

Short version what is good for us?

MGI Pharam being chased for money
OSI Pharam due to pay 19mil
Breast cancer deal expected to fetch 19mil going by current rumour

and there is more ;-)

Boston US- October 06
http://www.discoveryontarget.com/06-RNAI.asp

http://www.eirx.com


AUDIO INTERVIEW
http://www.wallstreetreporter.com/interview.php?id=18589&player=wma


MGI Pharma
----------
http://www.eirx.com/eirx_heading_images/Vaccine%20Antigens%20v2.0.pdf#search=%22mgi%20pharma%20zyc300%22

http://www.mgipharma.com/


Current Patents:-
----------------
http://v3.espacenet.com/results?sf=a&FIRST=1&CY=gb&LG=en&DB=EPODOC&TI=&AB=&PN=&AP=&PR=&PD=&PA=eirx&IN=&EC=&IC=&=&=&=&=&=

http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006037993&F=0

http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP1601969&F=0


VERY DETAILED INDEPTH PRESENTATION PDF. All you need to know about EiRX.
------------------------------------------------------------------------
http://www.eirx.com/eirx_heading_images/EiRx%20-%20EPIC%20220606.pdf


Market research report: -
------------------------
http://www.marketresearch.com/product/display.asp?productid=1320831&g=1


EiRX Exhibiting & or Presenting
-------------------------------

Bio-Japan- September 06
http://expo.nikkeibp.co.jp/biojapan/2006/eng/report004.html

Boston US- October 06
http://www.discoveryontarget.com/06-RNAI.asp

I assume it is Jerry Adams from item 20 of 24 on page 1 that is the good news?

anyone any opion on why the 10% drop today?

bad news on pharma.. thats what.. to do with share options.. was nothing to do with us, but it effected almost all the sp's

raving

8p I think i saw a flying elephant ??

Enzyme inhibitor produces stable disease in patients with advanced solid cell cancers
Phase II trials initiated
Prague, Czech Republic: Preliminary trials of a MEK enzyme inhibitor have shown that it is capable of producing long-lasting stable disease in patients with advanced solid cancers. Tests showed that the drug inhibited key targets in the patients' tumours, and now it is being tested in phase II clinical trials.

Professor Alex Adjei told the EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Prague today (Wednesday 8 November) that the drug AZD6244 (ARRY-142886) [2] inhibited MEK1/2 an enzyme that plays an important role in the Ras/Raf/MEK/ERK cell signalling pathway, which regulates cell proliferation and survival. Activation of this pathway has been implicated in a number of cancers, including lung, pancreatic, colon, melanoma and thyroid cancer.

"Laboratory studies have shown that AZD6244 has an effect on human tumours at nanomolar concentrations, and the first part of the phase I clinical trial has determined the maximum tolerated dose and the safety of the compound. Results from this second part of the trial demonstrate that a dose of 100mg of AZD6244 is well tolerated, produces a high incidence of long-lasting stable disease, and is associated with a profound inhibition of the cell signalling protein pERK and a reduction in cell proliferation which indicates that the drug is working against the tumours," said Prof Adjei, who was professor of oncology at the Mayo Clinic, Rochester, USA, before moving in October to be the senior vice-president for clinical research and chair of the Department of Medicine at the Roswell Park Cancer Institute, Buffalo, USA.

Prof Adjei and his colleagues at the Mayo Clinic, University of Colorado Health Sciences Center and Fox Chase Cancer Center recruited into the second part of the trial 34 patients with advanced cancers, including melanoma, breast, lung and colorectal cancers. Approximately 40% of the patients had melanoma. The researchers were particularly interested in this tumour type because a large proportion harbour B-Raf mutations, and tumours with these mutations may be highly sensitive to MEK inhibitors.

The patients were randomised to receive 100 or 200mg doses, twice a day for 28-day cycles. The larger dose proved to be too high for continuous dosing due to adverse side effects, but the smaller dose was well tolerated over a prolonged period.

The researchers tested biopsy tissue taken from the patients both before and after dosing. They found that the pERK protein was reduced by 77%. They also looked at another protein, Ki-67, which is used as a marker for cell proliferation. After dosing, there was a reduction in Ki-67 in nine out of 20 patients, and in five of those nine patients the reduction was at least 50% or more.

"We found that after 15 days of dosing, AZD6244 continued to inhibit pERK at times when concentrations of the drug in the blood were at their lowest levels between doses. At the lowest concentration, 400 nanograms of the compound per microlitre of plasma still corresponded to a 35-44% inhibition of pERK," said Prof Adjei.

Overall, 39 of 57 patients completed at least one cycle of treatment with AZD6244. After completion of the second cycle, 19 (49%) had stable disease, and nine of these patients (six melanoma, one each of breast cancer, non-small cell lung cancer and medullary thyroid cancer) remained stable for five or more months (range, 5-14+ months; median, 6 months). Two patients, one with thyroid cancer and the other with melanoma, continue to receive treatment with AZD6244 after one year. Sixteen of the 20 patients with melanoma completed at least one cycle of treatment. Twelve had stable disease after completion of cycle two, with stable disease persisting for at least five months in six patients (range, 5 - 13+ months; median, 6.5 months).

Prof Adjei said: "This drug shows initial promising results. It appears to be able to target cancers with over-activation of MEK and associated cell signalling pathways in an efficient manner. Furthermore, it is easy to give to patients as it comes in an oral formulation that can be swallowed. As a result, a number of phase II clinical trials have been initiated in patients with melanoma, pancreatic, lung and colon cancers."

###
Embargoed: 12.30 hrs CET Wednesday 8 November 2006

Abstract no: 26

[1] EORTC [European Organisation for Research and Treatment of Cancer, NCI [National Cancer Institute], AACR [American Association for Cancer Research]. [2] AZD6244 (ARRY-142886), an MEK inhibitor, was invented by Array BioPharma and is being co-developed with AstraZeneca. Array BioPharma sponsored Prof Adjei's study.

Despite of 'Spudheads' ramping, ERX are owed monies from companies using thier patents, should be rerated soon.

I know... master. I have enough emails saying they are chasing the money..

so it should be with us pretty darned soon

up up and away

up and away again

Are you talking about your self again PH ! ;)

NEWS FLASH!!!!! - HOODS ON THE RUN

So PH when will the news be ref payments

the fact is, I heard that these are in the shares mag tomorrow.. thats why the rise..

From who PH AND No porkies

http://www.scottish-enterprise.com/sedotcom_home/news-se/news-fullarticle.htm?articleid=192953

DATE: 24/Jan/2006

Ten of Scotlands leading companies and universities specialising in oncology research and development are participating in a trade mission to Massachusetts to develop closer links with global pharmaceutical companies based in the region.


The trip, which has been co-ordinated by Scottish Development Internationals life sciences team, will enable participants to meet with the US-based companies and identify how the work of Scottish based universities and companies could help advance the work of these companies in developing new treatments for cancer related illnesses.


Massachusetts has one of the largest concentrations of life sciences companies in the world with more than 280 companies and 30,000 employees working in the sector and an internationally renowned academic base. The Scottish delegation will be meeting some of the worlds leading pharmaceutical and biotechnology companies including Pfizer, Amgen and Genzyme to help open up new business opportunities.


The US companies will learn about Scotlands leading oncology centres of excellence, including the recently opened Beatson Institute at the University of Glasgows Garscube Estate and the University of Edinburghs Cancer Research Centre, which has been developed in partnership with Cancer Research UK. Leading Scottish companies such as Cyclacel Pharmaceuticals, CXR Biosciences and EiRx Therapeutics will also be attending to identify potential collaborative opportunities with the US-based firms.


Ian Leslie, team leader of the Scottish Development International Life Sciences team says: Boston and the wider Massachusetts state is regarded as one of the worlds leading life sciences locations and home to some of the worlds biggest pharmaceutical and biotech companies. Scotlands world class reputation in the oncology field has helped us get the foot in the door with these global firms and this trip will be hugely important in promoting Scotlands strengths in oncology research and developing new opportunities for collaborative working and new business opportunities for Scottish based organisations.


Scottish Biomedical, a drug discovery services company based in Glasgow, is one of the companies participating and hopes the trip will lead to developing new relationships overseas.


Simon Bury, Business Development Director of Scottish Biomedical, says: The US is obviously a very lucrative market for life sciences and Massachussets is a key market to target. This trip is enabling us to meet with a number of global companies and hopefully develop new relationships to capitalise on our existing contacts overseas.


Oncology is one of Scotlands leading areas of life sciences research and one which has significant commercial potential. There are almost fifty major research groups, centre of excellence and departments within eight Scottish Universities and Research Institutes, working to understand the causes of different cancers and developing new treatments. There is also a growing base of companies actively looking at drug discovery and development to develop new cancer therapeutics.


The full list of organisations participating in the trade mission are: Accuro Biologics Ltd; CXR Biosciences; Cyclacel Pharmaceuticals; EiRx Therapeutics PLC; Nexus Oncology; Scottish Biomedical; University of Aberdeen; University of Dundee; University of Edinburgh and University of Glasgow.

http://www.biologynews.net/archives/2007/01/24/reactivated_gene_shrinks_tumors.html

READ THIS LINK.. WHY THE HELL IS THE SHARE PRICE THIS LOW, WE ARE WORTH 100'S OF MILLIONS.. ALL THIS INFO ON P53, THIS ARTICLE STATES 100% REDUCTION IN TUMOURS.. AND WE ARE AT THE FOREFRONT OF THIS.

There is no mention of ERX in your link, unless they are hiding behind the name of Massachusetts Institute of technology.

read the one above it.. dope!!!

here read this link and tell me if ERX are not mentioned, i think you will find they are

http://www.scottish-enterprise.com/sedotcom_home/news-se/news-fullarticle.htm?articleid=192953

http://www.billamag.net/focus-text-main-quoted.asp?FocusTextID=33

this is about ERX and P53..

then read this about the recent news on P53

http://news.independent.co.uk/uk/health_medical/article2183853.ece

WHY IS THE MARKET NOT RESPONDING TO THIS NEWS, 100% DECREASE IN SIZE OF TUMOUR IS A MAJOR BREAKTHROUGH

Hey you ramping a...hole, who do you think you are calling a dope. Since I started following this thread mainly for a laugh at you, all I have gleaned from it, is a fall in the price of ERX. Wether this is justified or not isn't the point. The point is that there was no mention of ERX in the link that you provided. The only mention of ERX in the second link, is that they are attending a trade conference, mentioned in the last line at the bottom of the page. They are hardly the forerunners in this but merely hangers on. That is the same as saying that if Shell strike oil all oil stocks will rise. Obviously you are a few slices short of a loaf. Good luck with your investment I think you may need it.

Hey you ramping a...hole, who do you think you are calling a dope. Since I started following this thread mainly for a laugh at you, all I have gleaned from it, is a fall in the price of ERX. Wether this is justified or not isn't the point. The point is that there was no mention of ERX in the link that you provided. The only mention of ERX in the second link, is that they are attending a trade conference, mentioned in the last line at the bottom of the page. They are hardly the forerunners in this but merely hangers on. That is the same as saying that if Shell strike oil all oil stocks will rise. Obviously you are a few slices short of a loaf. Good luck with your investment I think you may need it.

LOL, watch this space oilrag.. you going to get a shock

UP 40% NOW LOL

Its about time. I'm also quite happy with what I'm holding thanks.

100% tumour reduction.. this has to be fantastic news, we will be worth billions, thats a cure is it not

i topped up 1mil @.O22 i am now holding 6 mil f::::k the rampers its all a gamble to a certain % but i can see this coming good

exactly... we hold the patent as well

100% reduction in solid tumour,.... we have a cure ;-)

we are worth billions

Calm down potatohead. Have another read of your news link, but first remove the rose coloured glasses.

In a study on laboratory mice, the scientists demonstrated that it was possible to arrest the growth of tumours by activating the p53 gene, which is known to be involved in cancer suppression. In some of the animals the tumours shrank by between 40 and 100 per cent and the experimental technique appeared to work on two quite different kinds of cancer that are also known to affect humans.

Note the range: 40 to 100% (NOT 100%)

And, as per your usual, there is absolutely no mention of EiRX in this article or in the published article in Nature magazine (which I have just read through). This work has been done by MIT and has no connection with EiRX whatsoever.

Representatives from EiRX (amongst a large group of other bio-techs) are going on a trade mission to the US where they will speak with MIT (amongst others), but that (in this context) is irrelevant. EDIT - Actually, there is no mention of them meeting with MIT - just says that they are going to Massachusettes.

Do you think that MIT are going to hand over their research to EiRX?

EIRX THERAPEUTICS PLC
("EiRx" or "the Company")

A 50% reduction in breast tumour volume size seen with Eirx lead molecule in
animal studies


Cork, Ireland - EiRx Therapeutics plc (AIM: ERX), the drug discovery company
developing targeted therapies for cancer, is pleased to announce the results of
preclinical studies, including preliminary in vivo animal efficacy for its lead
compound ERX3722.

A lead series of molecules (which included ERX3722) was identified from a screen
of kinase inhibitors using EiRx's EnPad(TM)technology. In cell line based in
vitro studies, these molecules demonstrated selective killing of breast cancer
cells over non-cancerous breast cells. Following a patent application in August
2005, ADME (Administration, Distribution, Metabolism, Excretion) studies
identified ERX3722 (Mw 331) as having favourable drug like properties in terms
of metabolic stability, serum binding, P-gp inhibition, Caco-2 efflux, and
Cyp450 inhibition. The compound is also very well tolerated with little or no
toxic effects on normal tissues detected, in maximum tolerated dose studies.

For the in vivo efficacy studies, mice bearing a subcutaneous human breast
cancer xenograft were treated with the compound at several different dosing
regimens. All treatment groups responded with a reduction in tumour volume,
relative to the untreated control, with the higher doses achieving a very
significant 50% reduction in tumour volume.

In addition to this significant efficacy, it was observed that during the
treatment regime, the mice did not show any toxic or side effects, such as
weight loss, associated with compound administration. This suggests that the
compound is highly selective for the tumour, unlike the more traditional cancers
therapies, where effectiveness can be limited due to associated toxicities.

"A reduction in tumour volume of 50% is seen by the National Cancer Institute in
America, and other leading authorities as being highly significant" said
Professor Tom Cotter, founder and CSO of EiRx. "We are now in active
discussions with a developmental company to further develop this molecule and to
prepare it for a future phase 1 clinical trial.

Commenting on the results, Dr. Finbarr Murphy, Managing Director of operating
subsidiary EiRx Therapeutics Ltd, said: "The efficacy and selectivity of the
molecule is very encouraging, and supports our approach of targeted apoptosis
therapy in the treatment of cancer to limit toxicity and side effects associated
with standard chemotherapy.

Across the seven major markets, 443,000 women were estimated to have developed
breast cancer in 2004, with an estimated 112,000 dying from the disease. The
incidence is forecast to increase annually at an average rate of 3%. The size
of the market for breast cancer drugs is $6.2 billion; representing 17% of the
total spend of the cancer market.

I hope you listened the MGI webcast last week by the way, ZYC300 is talked about

there also a slideshow and ZYC300 it all over it..

http://media.corporate-ir.net/media_files/Phoenix/client//73/73842/Slides/1491262/Decks/c3227a87-239b-489c-80c6-304224e5aa92/slide004.jpg

Adjusted To GAAP Reconciling Items:
1.Amortization of product intangibles
2.Stock based compensation expense
3.License and milestone payments
4.Restructuring expenses

they are now moving into validated clinic for zyc300..

http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=MOGN&item_id=1491262

suggest you listen to it, it looks like we could get further news this week, phase i/iib is done basically and now moving on

started to move up.. up 5%, large trades starting to show up, due to problem with monitor price rise not showing on monam but is on other websites

Kat
are those [2m x2 &5m x 1] buys or sells? judging by your last do you think they are buys.
Alex

I believe they are shorts starting to close actually. I believe there are going to be a lot more this afternoon.. I am expecting a big update tonight on the MGI webcast as last week they started talking about our product and that more news was coming very shortly. in fact todays webcast was brought forward from tomorrow, the webcast is at 4.30, so if we do get the news I am expecting.. then an rns should be issued first thing, remember zyc300 last week they said it is now in validated clinic, which means the results are out ahead of 1st April 2007.. and by all accounts its good news as well